Log in to search using one of your social media accounts:

 

Personalizing cancer therapies may combat resistance to targeted therapy drugs

(Massachusetts General Hospital) Massachusetts General Hospital physicians report the case of a patients whose lung cancer was re-sensitized to crizotinib, a first-generation targeted therapy drug, by a mutation conferring resistance to a more selective, next-generation ALK inhibitor.
Source: EurekAlert! - Cancer - Category: Cancer & Oncology Source Type: news

Related Links:

Authors: Ma J, Xu H, Wang S Abstract Lung cancer is the leading cause of cancer death worldwide due to its late diagnosis and poor outcome. Immunotherapy is becoming more and more encouraging and promising in lung cancer therapy. Myeloid-derived suppressor cells (MDSCs) are the main tumor suppressor factors, and the treatment strategy of targeting MDSCs is gradually emerging. In this review, we summarize what is currently known about the role of MDSCs in lung cancer. In view of the emerging importance of MDSCs in lung cancer, the treatment of targeting MDSCs will be useful to the control of the development and prog...
Source: Journal of Immunology Research - Category: Allergy & Immunology Tags: J Immunol Res Source Type: research
This report describes a case in which evaluation of tumor sequencing results by a molecular tumor board (MTB) led to rediagnosis of a non-small cell lung cancer as highly aggressive NUT midline carcinoma, with implications for targeted therapy using an investigational bromodomain and extraterminal (BET) inhibitor. We discuss the molecular biology and diagnosis of this rare tumor, and suggest how improved annotation of tumor sequencing reports and multidisciplinary expertise of MTBs can facilitate timely diagnosis of rare tumors and application of potential targeted therapies. PMID: 29752320 [PubMed - in process]
Source: Journal of the National Comprehensive Cancer Network : JNCCN - Category: Cancer & Oncology Tags: J Natl Compr Canc Netw Source Type: research
CONCLUSION: NDRG1 is an important modulator linking DNA damage response and hypoxia-related cellular stress response during the development of drug resistance to cisplatin/CMNa in lung cancer. Targeting both NDRG1 and ERCC1 may be a viable strategy for overcoming drug resistance in cancer therapy, and has significant clinical implications. PMID: 29768183 [PubMed - as supplied by publisher]
Source: The International Journal of Biochemistry and Cell Biology - Category: Biochemistry Authors: Tags: Int J Biochem Cell Biol Source Type: research
Authors: Wu L, Yang L Abstract As a non-histone chromatin-associated protein, high-mobility group box-1 (HMGB1) performs a pivotal function in various human diseases, including autoimmune diseases, neurodegenerative diseases and cancer. Overexpression of HMGB1 has been demonstrated in numerous types of cancer, including breast cancer, colorectal cancer, lung cancer and hepatocellular carcinoma. However, the underlying mechanism of HMGB1 function in lung cancer remains to be elucidated. The present study aimed to analyze, and summarize the role and mechanism of HMGB1 in lung cancer by retrieving available literature...
Source: Oncology Letters - Category: Cancer & Oncology Tags: Oncol Lett Source Type: research
Authors: Katz A, Barash U, Boyango I, Feld S, Zohar Y, Hammond E, Ilan N, Kremer R, Vlodavsky I Abstract Heparanase, the sole heparan sulfate (HS) degrading endoglycosidase, regulates multiple biological activities that enhance tumor growth, metastasis, angiogenesis, and inflammation. Heparanase accomplishes this by degrading HS and thereby facilitating cell invasion and regulating the bioavailability of heparin-binding proteins. HS mimicking compounds that inhibit heparanase enzymatic activity were examined in numerous preclinical cancer models. While these studies utilized established tumor cell lines, the curren...
Source: Oncotarget - Category: Cancer & Oncology Tags: Oncotarget Source Type: research
This article is intended to provide readers with an overview of chemistry, pharmacokinetic, pharmacodynamic and safety profile of brigatinib, which addresses an unmet medical need.
Source: Saudi Pharmaceutical Journal - Category: Drugs & Pharmacology Source Type: research
Development and Evaluation of a Novel Drug Delivery: Soluplus®/TPGS Mixed Micelle Loaded With Piperine In Vitro and In Vivo. Drug Dev Ind Pharm. 2018 May 02;:1-20 Authors: Ding Y, Wang C, Wang Y, Xu Y, Zhao J, Gao M, Ding Y, Peng J, Li L Abstract BACKGROUND: Although piperine can inhibit cells of tumors, the poor water solubility restricted its clinical application. This paper aimed to develop mixed micelles based on Soluplus® and TPGS, to improve the aqueous solubility and anti-cancer effect. METHODS: Piperine -loaded mixed micelles were prepared using a thin- film hydration method, and th...
Source: Drug Development and Industrial Pharmacy - Category: Drugs & Pharmacology Tags: Drug Dev Ind Pharm Source Type: research
Publication date: Available online 3 May 2018 Source:Pharmacological Research Author(s): Zhangting Yao, Jieqiong Zhang, Bo Zhang, Guikai Liang, Xi Chen, Fengqi Yao, Xiaqing Xu, Honghai Wu, Qiaojun He, Ling Ding, Bo Yang Although M2-like tumor-associated macrophages (TAMs) have been considered as a vital therapeutic target in cancer therapy due to their role in promoting tumor progression and metastasis, very few compounds have been identified to inhibit M2-like polarization of TAMs. Here, we showed that Imatinib significantly prevented macrophage M2-like polarization induced by IL-13 or IL-4 in vitro, as illustrated by re...
Source: Pharmacological Research - Category: Drugs & Pharmacology Source Type: research
CONCLUSIONS: Numerous studies have indicated that lncRNA PVT1 will most likely become a novel target for cancer therapy with the deepening systematic research. PMID: 29739059 [PubMed - in process]
Source: Clinical Lung Cancer - Category: Cancer & Oncology Authors: Tags: Clin Lab Source Type: research
After an'extraordinary week'of advances in lung cancer, Dr Mark Kris explains why checkpoint inhibitors now play a major role in lung cancer therapy.Medscape Oncology
Source: Medscape Today Headlines - Category: Consumer Health News Tags: Hematology-Oncology Commentary Source Type: news
More News: Cancer | Cancer & Oncology | Cancer Therapy | Hospitals | Lung Cancer